Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
bioXXmed AGHAM:T5O 34 Median PS Value is €0.00 as of Jul. 16, 2026. GuruFocus rates HAM:T5O with a GF Score™ of 34/100 and a GF Value™ of €9.07 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 277 Biotechnology companies, bioXXmed AG ranks worse than 361010.47% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. bioXXmed AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.063. bioXXmed AG's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is €0.00.
As of today (2026-07-16), bioXXmed AG's share price is €0.77. bioXXmed AG's Median PS Value is €0.00. Therefore, bioXXmed AG's Price to Median PS Value for today is 0.00.
The historical rank and industry rank for bioXXmed AG's Median PS Value or its related term are showing as below:
HAM:T5O's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.64 * Ranked among companies with meaningful Price-to-Median-PS-Value only.
bioXXmed AG (HAM:T5O) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
bioXXmed AG's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.77
/
0.00
=
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioXXmed AG Median PS Value Related Terms
bioXXmed AG Median PS Value Historical Data
* Premium members only.
The historical data trend for bioXXmed AG's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:T5O vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, bioXXmed AG's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
bioXXmed AG Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, bioXXmed AG's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where bioXXmed AG's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 0.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. bioXXmed AG's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.063.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
bioXXmed AG (HAM:T5O) has a Median PS Value of €0.00 as of Jul. 16, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on bioXXmed AG and its competitors. According to the industry distribution chart, bioXXmed AG ranks #999999 out of 277 companies in the Biotechnology industry.
Is bioXXmed AG's Median PS Value too high?
bioXXmed AG's current Median PS Value is €0.00. Based on the distribution chart, bioXXmed AG ranks #999999 out of 277 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, bioXXmed AG has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does bioXXmed AG's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, bioXXmed AG ranks #999999 out of 277 companies for Median PS Value. This places bioXXmed AG in the lower half of its industry. The industry median Median PS Value is 0.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.64, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on bioXXmed AG and its competitors. For the Biotechnology industry, the median Median PS Value is 0.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. bioXXmed AG's current Median PS Value is €0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is bioXXmed AG stock overvalued right now?
Based on GuruFocus' analysis, bioXXmed AG (HAM:T5O) is currently considered Possible Value Trap. The stock's GF Value™ is €9.07, compared to a current price of €0.77 — trading 91.5% below its estimated fair value. The current Median PS Value is €0.00. bioXXmed AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For bioXXmed AG (HAM:T5O), the current Median PS Value is €0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is bioXXmed AG (HAM:T5O) Overvalued in 2026?
Based on GuruFocus' analysis, bioXXmed AG stock appears to be undervalued.
The current stock price of €0.77 is trading 91.5% below its estimated GF Value™ of €9.07.
GuruFocus considers bioXXmed AG to be Possible Value Trap.
Key valuation signals for HAM:T5O:
Median PS Value: €0.00
GF Value™: €9.07 vs. price of €0.77 (91.5% below fair value)
No single metric tells the full story. See the HAM:T5O stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
bioXXmed AG is an investment and holding company in the technology sector. It originated from CytoTools GmbH, a successful German technology enterprise from the pharmaceuticals and medical products field.
34GF Score
Get the complete analysis for HAM:T5O
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:T5O has been successfully added to your 
